Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 449

Results For "CHI"

5487 News Found

We have built new AI platforms like REILI to meet current needs: Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India
interviews | March 30, 2022

We have built new AI platforms like REILI to meet current needs: Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India

Fujifilm has been at the forefront of medical imaging and healthcare informatics. It’s developing new AI platforms to address medical challenges. Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India gives us an insight in an interview with Thomas C. Thottathil, Editor, indianpharmapost.com


ASC Therapeutics gets green light to advance gene therapy for Hemophilia A
Biotech | March 30, 2022

ASC Therapeutics gets green light to advance gene therapy for Hemophilia A

A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies


Govt clears 49 applicants for PLI in Bulk Drugs
News | March 30, 2022

Govt clears 49 applicants for PLI in Bulk Drugs

The selected 49 applications are from 33 companies. Out of these 33 companies, 13 are Micro, Small and Medium Enterprises (MSMEs) besides some newly incorporated entities


Sanofi and IGM Biosciences team up to commercialise IgM antibody agonists
Biotech | March 30, 2022

Sanofi and IGM Biosciences team up to commercialise IgM antibody agonists

Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets


OPPI summit calls for collaboration across stakeholders
News | March 30, 2022

OPPI summit calls for collaboration across stakeholders

The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India


Sun Pharma gets exclusive patent licence for Vortioxetine
News | March 30, 2022

Sun Pharma gets exclusive patent licence for Vortioxetine

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults


GenScript wins Best CDMO award for the third time
News | March 30, 2022

GenScript wins Best CDMO award for the third time

The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".


USFDA approves CartiHeal's implant for the treatment of cartilage and osteochondral defects
Drug Approval | March 30, 2022

USFDA approves CartiHeal's implant for the treatment of cartilage and osteochondral defects

Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint


NAMSA to acquire European-based Medanex clinic
Biotech | March 30, 2022

NAMSA to acquire European-based Medanex clinic

World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.


Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes
Drug Approval | March 29, 2022

Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes

Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults